Skip to content
10-Q

Quarterly Report

Fulgent Genetics, Inc. FLGT

0001193125-26-199065

← back to feed
Filed
May 1, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 28.4M sh
Shares Diluted Q1 2026 · Mar 31, 2026 30.88M sh
Shares Diluted Q1 2026 · Mar 31, 2025 30.83M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $40.08M
Stock Repurchased Q1 2026 · Mar 31, 2025 $8.68M
Capex Q1 2026 · Mar 31, 2026 $5.2M
Capex Q1 2026 · Mar 31, 2025 $4.72M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $7.1M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.43M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $23.4M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $50.19M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $67.28M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.05B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.11B
Current Liabilities Q1 2026 · Mar 31, 2026 $90.13M
Current Liabilities Q1 2026 · Dec 31, 2025 $84.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $112.22M
Total Liabilities Q1 2026 · Dec 31, 2025 $106.81M
Current Assets Q1 2026 · Mar 31, 2026 $479.04M
Current Assets Q1 2026 · Dec 31, 2025 $550.49M
Total Assets Q1 2026 · Mar 31, 2026 $1.16B
Total Assets Q1 2026 · Dec 31, 2025 $1.21B
Sga Expense Q1 2026 · Mar 31, 2026 $27.68M
Sga Expense Q1 2026 · Mar 31, 2025 $25.29M
Rd Expense Q1 2026 · Mar 31, 2026 $14.18M
Rd Expense Q1 2026 · Mar 31, 2025 $12.4M
Net Income Q1 2026 · Mar 31, 2026 −$24.83M
Net Income Q1 2026 · Mar 31, 2025 −$11.53M
Operating Income Q1 2026 · Mar 31, 2026 −$34.62M
Operating Income Q1 2026 · Mar 31, 2025 −$19.8M
Gross Profit Q1 2026 · Mar 31, 2026 $21.49M
Gross Profit Q1 2026 · Mar 31, 2025 $28.35M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $49.65M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $45.12M
Revenue Q1 2026 · Mar 31, 2026 $71.14M
Revenue Q1 2026 · Mar 31, 2025 $73.46M